Recent developments highlight NovaBridge’s clinical progress and regulatory advancements, including positive trial results and FDA alignment for accelerated approval.

• NovaBridge secured FDA alignment on an accelerated approval pathway for givastomig in gastric cancer, indicating regulatory progress [N1].
• The company reported positive topline results from a Phase 2a study of VIS-101, supporting clinical advancement [N2].
• NovaBridge dosed the first patient in a Phase 2 study of givastomig in gastric cancer, with data expected in 2027 [N3].
• Positive Phase 1b results were reported for givastomig in metastatic gastric cancer, demonstrating early clinical efficacy [N4].
• Promising Phase 1 results were announced for ragistomig, a 4-1BB x PD-L1 bispecific antibody, expanding the pipeline [N5].

The company has demonstrated progress in clinical development with positive Phase 1b and Phase 2a results for key drug candidates, including givastomig and VIS-101. Securing FDA alignment on an accelerated approval pathway for givastomig in gastric cancer represents a significant regulatory milestone. The strong liquidity position provides financial flexibility to support ongoing research and development activities. Strategic partnerships, such as with AbbVie, enhance development capabilities and potential market reach. The company’s diversified pipeline across oncology and ophthalmology offers multiple avenues for future growth.

NovaBridge faces risks typical of clinical-stage biotechnology companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The company reported a net loss of $46.3 million in 2025, reflecting ongoing investment without current profitability. Market risks include exposure to interest rate fluctuations and foreign currency exchange rates, which could impact financial results. The company’s reliance on collaborations and licensing agreements introduces counterparty risk. Additionally, the company’s ADS structure involves fees and charges that may affect shareholder returns. The biotechnology sector’s competitive landscape and potential delays in clinical development pose execution risks.

NovaBridge’s moat is based on its innovative biotechnology platform and its pipeline of novel drug candidates in oncology and ophthalmology. The company’s strategic collaborations, such as the partnership with AbbVie, provide access to development and commercialization resources. Its focus on bispecific antibodies and accelerated regulatory pathways, including FDA alignment for givastomig, supports potential differentiation. The company’s intellectual property holdings and specialized research capabilities contribute to its competitive positioning. However, as a clinical-stage biotechnology company, its moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: The company’s drug candidates are in various stages of clinical trials, and there is inherent uncertainty regarding successful trial outcomes and regulatory approvals.
• Financial Risk: NovaBridge reported a net loss of $46.3 million in 2025 and depends on its liquidity position and potential future financing to fund operations.
• Market Risk: Exposure to interest rate fluctuations and foreign currency exchange rates may affect financial performance, although current direct foreign exchange risk is limited.
• Regulatory Risk: The company’s ability to secure regulatory approvals, including accelerated pathways, is critical and subject to regulatory agency decisions.
• Operational Risk: The company’s reliance on collaborations and licensing agreements introduces risks related to counterparties and execution of strategic partnerships.

• NovaBridge Biosciences is a global biotechnology platform company focused on innovative treatments, with a recent name change from I-Mab effective October 29, 2025.
• The company operates primarily in oncology and ophthalmology therapeutic areas, with subsidiaries including Visara Inc. (ophthalmology) and Bridge Health Bio-Tech (intellectual property holding).
• NovaBridge has ongoing clinical development programs including givastomig for gastric cancer, VIS-101, and ragistomig, a 4-1BB x PD-L1 bispecific antibody.
• The company has secured FDA alignment on an accelerated approval pathway for givastomig in gastric cancer.
• Recent clinical milestones include positive Phase 1b results for givastomig in metastatic gastric cancer, positive topline results from a Phase 2a study of VIS-101, and promising Phase 1 results for ragistomig.
• NovaBridge dosed the first patient in a Phase 2 study of givastomig in gastric cancer, with data anticipated in 2027.
• The company reported full year 2025 financial results with cash and cash equivalents of approximately $210.6 million as of December 31, 2025, and short-term investments of $210,000, resulting in a strong liquidity position with a current ratio of 8.09 and cash ratio of 7.84.
• Revenue reported was $632,000 for the year ended December 31, 2025, with a net loss of $46.3 million for the same period.
• The company’s net loss per share was approximately $0.21 for continuing operations in 2025.
• NovaBridge’s financial statements are prepared under U.S. GAAP and include consolidated subsidiaries.
• The company has a history of collaboration and licensing agreements, including a global strategic partnership with AbbVie for lemzoparlimab development and commercialization.
• The company has implemented comprehensive cybersecurity risk management procedures and has not experienced any material cybersecurity incidents as of the latest report.
• NovaBridge’s American Depositary Shares (ADS) are issued through Citibank as depositary, with a ratio of 10 ADSs representing 23 ordinary shares.
• The company’s business risks include market risks related to interest rates and foreign currency exchange rates, with limited direct foreign exchange risk currently.
• The company’s recent news and SEC filings provide detailed disclosures on clinical progress, financial condition, and governance.
• The company’s insider trading policy was updated in April 2026 to align with current operations.
• NovaBridge’s consolidated financial statements reflect the accounts of the company and all subsidiaries with controlling interest, eliminating inter-company balances.
• The company’s liquidity position as of December 31, 2025, includes $217.5 million in current assets and $26.9 million in current liabilities.
• The company’s research and development expenses include costs related to personnel, clinical trials, and in-licensed drug candidates.
• NovaBridge’s revenue recognition follows ASC 606, recognizing revenue when control of goods or services transfers to customers.
• The company’s recent news includes multiple clinical trial updates and regulatory progress announcements in early 2026.
• NovaBridge completed a sale of a portion of its series C shares in TJ Biopharma in January 2026, reducing ownership to approximately 9.01%.